ライフサイエンスコーパス: pointes

1 orphic ventricular tachycardia ('torsades de pointes').

2 ythmias (eg, long QT syndrome and torsade de pointes).

3 related ventricular arrhythmias (torsades de pointes).

4 T interval and/or development of torsades de pointes).

5 long the QT interval and provoke torsades de pointes.

6 methadone may be associated with torsade de pointes.

7 e thought to trigger episodes of torsades de pointes.

8 arket after being associated with torsade de pointes.

9 tion are not capable of inducing torsades de pointes.

10 ia displaying characteristics of torsades de pointes.

11 was QT prolongation resulting in Torsade de pointes.

12 ial arrhythmias, but it can cause torsade de pointes.

13 the QT interval but rarely causes torsade de pointes.

14 ially lethal arrhythmia known as torsades de pointes.

15 the potential for development of torsade de pointes.

16 ricular arrhythmias, specifically torsade de pointes.

17 ymorphic ventricular tachycardia torsades de pointes.

18 nd an increased propensity toward torsade de pointes.

19 the link between hypokalemia and torsade de pointes.

20 usceptibility to arrhythmias like Torsade de Pointes.

21 reatening ventricular arrhythmia, Torsade de Pointes.

22 to drug-induced QT prolongation/torsades de pointes.

23 ificant predictor of drug-induced torsade de pointes.

24 and the lethal cardiac arrhythmia torsade de pointes.

25 polarizations thought to trigger torsades de pointes.

26 the potentially fatal arrhythmia torsades de pointes.

27 T interval syndrome (diLQTS) and torsades de pointes.

28 rrhythmic agents known to promote torsade de pointes.

29 abnormal heart rhythms, including torsade de pointes.

30 erventions to reduce the risk of torsades de pointes.

31 h the rare adverse drug reaction torsades de pointes.

32 ts including QT prolongation and torsades de pointes.

33 mine the risk of rare events like torsade de pointes.

34 tion of L-type channels, such as Torsades de Pointes.

35 rug-induced long QT syndrome and torsades de pointes.

36 afterdepolarizations (EADs), and torsade de pointes.

37 n are more vulnerable than men to torsade de pointes.

38 ation with the associated risk of torsade de pointes.

39 ndividuals to QT prolongation and torsade de pointes.

40 associated with case reports of torsades de pointes.

41 ere was 1 episode of nonsustained torsade de pointes (1 of 70, 1.4%) after ibutilide.

42 ort of consecutive patients with Torsades de Pointes; (3) the relationship between K(+) channel mRNA

43 arrests, with one resulting from Torsade de Pointes (6%).

44 Torsades de pointes, a form of ventricular tachycardia, has been rep

45 olong the QT interval and lead to torsade de pointes, a life-threatening ventricular arrhythmia, this

46 t in cases of QTc prolongation or torsade de pointes after dofetilide (a known proarrhythmic drug) an

47 acebo group (0.3% versus 0.1% for torsade de pointes and 0.9% versus 0.2% for severe neutropenia).

48 th complex arrhythmias including torsades de pointes and 2 degrees atrioventricular block.

49 Macrolides are known to cause torsade des pointes and other ventricular arrhythmias, and a recent

50 The incidences of torsade de pointes and severe neutropenia (absolute neutrophil coun

51 t women carry a greater risk for Torsades de pointes and sudden cardiac death than do men.

52 , possibly increasing the risk of Torsade de pointes and sudden cardiac death.

53 Prediction of torsade de pointes and sudden death can be improved by examining do

54 hanisms and establish the risk of torsade de pointes and sudden death with antipsychotic drugs.

55 dol have been documented to cause torsade de pointes and sudden death, the most marked risk is with t

56 f the role of noncardiac drugs in torsade de pointes and sudden death.

57 On the other hand, drug-induced torsades de pointes and symptomatic long QT syndrome have a female p

58 Another developed sustained torsade de pointes and was treated effectively with direct-current

59 morphic ventricular tachycardia (torsades de pointes) and sudden death.

60 result in ventricular arrhythmia (torsade de pointes) and sudden death.

61 orphous ventricular tachycardia (torsades de pointes), and sudden arrhythmic death.

62 s defined as syncope, documented torsades de pointes, and aborted cardiac arrest or sudden cardiac de

63 e is burdened by QT prolongation, torsade de pointes, and sudden cardiac death.

64 Cases of QT prolongation, torsades de pointes, and sudden death have been reported with arseni

65 amilial and drug-induced cases of torsade de pointes, and the recognition of the role of noncardiac d

66 QT interval prolongation and torsade de pointes are associated with astemizole intake and have b

67 rolongation and potentially fatal Torsade de Pointes arrhythmia.

68 s that are associated with lethal Torsade de Pointes arrhythmia.

69 ective against dofetilide-induced torsade de pointes arrhythmias (TdP), while maintaining calcium hom

70 ated with an increased risk for Torsades des Pointes arrhythmias and sudden death.

71 Torsade de pointes arrhythmias could be induced during epicardial,

72 n the electrocardiogram and cause torsade de pointes arrhythmias not by direct block of the cardiac p

73 associated with life-threatening torsade de pointes arrhythmias that develop as a consequence of the

74 ave been associated with syncope, torsade de pointes arrhythmias, and sudden cardiac death.

75 nd fibrillations reminiscent of Torsades des Pointes arrhythmias, and they exhibit severely increased

76 predispose to the development of torsade de pointes arrhythmias.

77 tracellular calcium may underlie torsades de pointes associated with intravenous tacrolimus.

78 re were 2 occurrences of nonfatal torsade de pointes, both in the haloperidol group.

79 0%) had NSVT, including 1 who had torsade de pointes, but most had <5 episodes.

80 ently causes QT-prolongation and torsades de pointes cardiac arrhythmias.

81 ct which patients are at risk for torsade de pointes, careful assessment of the risk to benefit ratio

82 Consistently in the Torsades de Pointes cohort, concomitant acute infections were highly

83 ing a persistent increase in TDR; Torsade de Pointes developed or could be induced only in the presen

84 a per se, determines the risk for torsade de pointes during atrioventricular block (AVB).

85 th diLQTS, defined as documented torsades de pointes during treatment with a QT-prolonging drug.

86 ing QT interval prolongation and torsades de pointes, errors in the use of medications that may prolo

87 bservation of QT prolongation and torsade de pointes found with astemizole intake may principally be

88 They examine the risk for torsade de pointes from antipsychotic drugs and estimate the freque

89 ongation, potassium channels, and torsade de pointes from both the long QT syndrome and drugs.

90 es of prolonged QTc interval and torsades de pointes have been described in HIV-infected patients on

91 ythmia/tachyarrhythmia in 12, and torsade de pointes in 2 patients).

92 s developed in 7 patients (5.8%) (torsade de pointes in 2), significant bradycardia in 20 (16.7%) (ra

93 bservation of QT prolongation and torsade de pointes in a patient with undetectable serum concentrati

94 ftercontractions occurred before torsades de pointes in an in vivo dog model of drug-induced long-QT1

95 ificant predictor of drug-induced torsade de pointes in an independent sample of 216 cases compared w

96 amine susceptibility to acquired torsades de pointes in chronic atrioventricular block and for compar

97 duced BVR (P<0.01), and abolished torsade de pointes in hearts treated with either 20 nmol/L E-4031 o

98 surface cause QT prolongation and torsade de pointes in patients treated with As(2)O(3).

99 e-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals.

100 been recognized as a hallmark of torsade de pointes in the acquired LQTS, plays a major role in the

101 the mode of onset of spontaneous torsade de pointes in the congenital long QT syndrome.

102 o electrophysiologic mechanism of torsade de pointes in the long QT syndrome is described, using as a

103 higher incidences of drug-induced torsade de pointes in women than in men are incompletely defined, a

104 ictors of risk for progression to torsade de pointes, in addition to the degree of QT prolongation, w

105 rdiac medications known to cause torsades de pointes, including fluoroquinolones and intravenous halo

106 ly reports of QTc prolongation or torsade de pointes increased from a mean of 0.3 (95% CI, 0.1 to 0.5

107 on effect of many drugs producing torsade de pointes is block of the rapidly activating component of

108 The risk of torsade de pointes is low in hospitalized patients with COVID-19 re

109 T interval and the occurrence of torsades de pointes is similar to more expensive alternative medicat

110 The progression to torsade de pointes may be less related to degree of QT prolongation

111 darone, and drugs associated with torsade de pointes may have contributed to poor outcomes early in t

112 differences in propensity toward torsade de pointes may reflect the relatively greater presence in m

113 r tachycardia, Brugada syndrome, torsades de pointes) may result in serious consequences, including s

114 ata suggest that cisapride caused torsade de pointes not only by blocking IKr but also by rescuing ce

115 Torsade de pointes occurred after an abrupt acceleration of CL, whi

116 Torsades de pointes occurred in 1 patient (0.1%) with COVID-19.

117 rsus WT (8/26; 31%; P<0.05), and Torsades de Pointes occurred more frequently (73% Cav3.1(-/-) versus

118 Two cases of torsade de pointes occurred, 1 on day 2 and the other on day 3 (0.8

119 fter ibutilide, only 1 episode of torsade de pointes occurred.

120 Torsade de pointes often occurs with underlying hypokalemia and bra

121 tricular block animals exhibited torsades de pointes on dofetilide, the arrhythmia was induced in onl

122 not VT storm, and no history of torsades de pointes or QT interval prolongation.

123 nce to suggest that this leads to torsade de pointes or sudden death.

124 the patients on sotalol developed Torsade de pointes or sustained ventricular arrhythmias.

125 e+/-azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported.

126 patients with QT prolongation or torsade de pointes, or both, associated with protease inhibitors, u

127 tachycardia, ventricular flutter, torsade de pointes, or ventricular fibrillation.

128 drug-induced long QT syndrome and torsade de pointes pose unique challenges for clinicians, researche

129 ed in a patient with drug-induced torsade de pointes precipitated by the IKr blocker cisapride.

130 All drugs that cause torsade de pointes prolong the QTc interval and bind to the potassi

131 culitis and leukoencephalopathy, torsades de pointes, pulmonary vasculopathy, and pulmonary edema.

132 rugs, patients with low risk for torsades de pointes receiving selected class III agents, in whom dat

133 atient suffered recurrent runs of torsade de pointes, refractory to aggressive medical management and

134 Drug-induced QT prolongation and torsades de pointes remain significant and often unpredictable clini

135 The incidence of torsade de pointes remains unknown.

136 ongation to be common (24%), with Torsade de Pointes representing 6% of in-hospital cardiac arrests.

137 ure was followed by an episode of torsade de pointes requiring immediate cardioversion.

138 on in hospitalized patients with torsades de pointes risk factors.

139 set of drugs with known clinical torsade de pointes risk was selected to develop and calibrate the i

140 nduced arrhythmias, particularly torsades de pointes, risk factors are well defined.

141 Torsades de Pointes score was relatively high with ibutilide alone a

142 The risk of torsades de pointes should be assessed in patients who are about to

143 nt with the propensity to induce torsades de pointes, substantially inhibits the current.

144 Torsades de pointes (TdP) +/-2 degrees atrioventricular block (AVB)

145 /L totally suppressed spontaneous torsade de pointes (TdP) and reduced the vulnerable window during w

146 long QT syndrome (LQTS) include torsades de pointes (TdP) and/or 2 degrees atrioventricular block, b

147 jects and may be associated with torsades de pointes (TdP) arrhythmia, we tested the hypothesis that

148 d and acquired long-QT associated torsade de pointes (TdP) arrhythmias, and sympathetic discharge is

149 cause of its propensity to induce torsade de pointes (TdP) arrhythmias.

150 Dose-dependent susceptibility to Torsade de Pointes (TdP) by class III drug dofetilide, 3, 10, and 3

151 chycardia with characteristics of torsade de pointes (TdP) developed in the presence of dl-sotalol.

152 re more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to

153 it hearts are more susceptible to torsade de pointes (TdP) in acquired long QT type 2 than males, in-

154 electrical instability leading to torsade de pointes (TdP) in LQTS are poorly understood.

155 tion (TDR) and the development of Torsade de Pointes (TdP) in models of LQT1, LQT2 and LQT3 forms of

156 re associated with initiation of torsades de pointes (TdP) in patients with acquired (a-) and congeni

157 study was to identify markers of torsades de pointes (TdP) in patients with drug-associated long QT s

158 may be related to the genesis of torsade de pointes (TdP) in patients with the long-QT (LQT) syndrom

159 sion of repolarization (TDR), and torsade de pointes (TdP) induced by beta-adrenergic agonists under

160 Drug-related torsade de pointes (TdP) is usually recognized within days of initi

161 The ventricular arrhythmia torsade de pointes (TdP) occurs after QT interval prolongation and

162 F, excessive QT prolongation and torsades de pointes (TdP) often occur shortly after sinus rhythm is

163 entry, giving rise to the typical torsade de pointes (TDP) pattern.

164 ion channel specific blocker was Torsades de Pointes (TdP) reentrant arrhythmia activations in 100% o

165 larization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2,

166 ciated with azimilide-associated torsades de pointes (TdP) ventricular tachycardia.

167 adjustment and the incidence of torsades de pointes (TdP) were identified.

168 ADs and the mechanisms underlying Torsade de Pointes (TdP) were investigated in a model of long QT sy

169 systolic activity and spontaneous torsade de pointes (TdP) were never observed, and stimulation-induc

170 n producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol

171 lmodulin inhibitor W-7 suppresses torsade de pointes (TdP) without shortening the QT interval, which

172 g-QT syndromes (diLQTS) can cause torsade de pointes (TdP), a life-threatening ventricular arrhythmia

173 ization and increases the risk of Torsade de Pointes (TdP), a potentially lethal arrhythmia.

174 with documented prolonged QTc and Torsade de Pointes (TdP), and in an adult woman with QTc >500 ms, a

175 ic risk and in particular risk of Torsade de Pointes (TdP), as indicated by prolongation of the QT in

176 sk of lethal arrhythmias, called Torsades de pointes (TdP), compared to the opposite sex.

177 g medications with known risk of torsades de pointes (TdP), which is associated with higher risk of s

178 ular block, T-wave alternans, and torsade de pointes (TdP).

179 red long-QT syndrome (aLQTS) and torsades de pointes (TdP).

180 g QRS morphology, better known as torsade de pointes (TdP).

181 ssociated with the development of torsade de pointes (TdP).

182 e-threatening arrhythmia known as Torsade de Pointes (TdP).

183 s can result in life-threatening torsades de pointes (TdP).

184 ulation despite its known risk of Torsade de pointes (TdP).

185 absent proarrhythmia markers for Torsade de Pointes (TdP).

186 23) and VA (n = 29 193) including torsade de pointes (TdP, n = 8163) reporting for 663 anticancer dru

187 luding the risk of drug-induced 'torsades de pointes' (TdP) arrhythmia, is a major concern in the dev

188 Women have a higher incidence of torsades de pointes than men, but it is not known if the risk of dru

189 tients present with short-coupled torsade de pointes, the genetics of which are poorly understood.

190 on disorders, or risk factors for torsade de pointes, there have been no serious cardiovascular event

191 ng medications can predispose to torsades de pointes, there is a relative paucity of information that

192 correlate with a higher risk of torsades de pointes, there is no established threshold below which p

193 uce acquired long QT syndrome and torsade de pointes through its interaction with the Purkinje fibers

194 substrate for the development of torsade de pointes under long-QT conditions.

195 nown if the risk of drug-induced torsades de pointes varies during the menstrual cycle.

196 Torsade de pointes ventricular tachyarrhythmia in the long QT syndr

197 ction potential and propensity to torsade de pointes ventricular tachycardia.

198 There were no cases of torsades de pointes, ventricular fibrillation, or polymorphic or sus

199 Twelve documented cases of torsade de pointes VT were noted.

200 ventricular tachycardia (VT), and torsade de pointes VT) in the antiarrhythmic drug arm of the AFFIRM

201 The incidence of torsade de pointes was 0.6% at five years (95% confidence interval

202 Documentation of the onset of torsade de pointes was available for 15 patients.

203 Pause-dependent torsade de pointes was clearly documented in 14 of the 15 patients

204 The primary outcome of torsade de pointes was not observed in the entire population.

205 The primary outcome of torsade de pointes was observed in 1 (0.015%) out of 6476 hospitali

206 When a drug associated with torsades de pointes was prescribed to a patient at moderate or high

207 as recorded in five patients, and torsade de pointes was recorded in seven other patients.

208 due to QTc prolongation, and no Torsades de Pointes was reported.

209 379 cases of QTc prolongation or torsade de pointes were associated with methadone.

210 ints, including the occurrence of torsade de pointes, were evaluated.

211 lapsed APL developed asymptomatic torsade de pointes, which resolved spontaneously and did not recur

212 The characteristic association of torsade de pointes with T-wave alternans and short-long cardiac seq

213 lymorphic ventricular tachycardia torsade de pointes, with drugs or other environmental stressors suc